In 2013, Zumsteg et al. proposed a refinement in the NCCN “intermediate risk” classification into two subcategories, “favorable intermediate-risk (FIR)” and “unfavorable intermediate-risk (UIR).” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant, ADT, favorable, intermediate, radiation, risk, unfavorable | 3 Comments »
Eastham et al. have recently reported — in the Journal of Clinical Oncology — results from a randomized Phase III trial of the surgical treatment of men with high-risk forms of localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: "high risk", ADT, androgen, chemohormonal, chemotherapy, CHT, deprivation, localized, neoadjuvant, prostatectomy, radical, trial | 1 Comment »
An upcoming article in the September issue of the journal Critical Reviews in Oncology/Hematology addresses issues related to the maintenance of sexual function for men with prostate cancer on androgen deprivation therapy (ADT). … READ MORE
Filed under: Uncategorized | Tagged: activity, ADT, androgen, deprivation, function, sex | 5 Comments »
Last month, we looked at Level 1 evidence (highest level, superseding all previous studies) that for unfavorable-risk patients, brachy boost therapy (BBT) — i.e., external beam therapy (EBRT) with a brachytherapy boost to the prostate — has better results when accompanied by 18 months of androgen deprivation therapy (ADT) (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, brachy boost, high, intermediate, radiation, risk, therapy | 3 Comments »
TROG 01.03 RADAR, begun in 2003, was a (partly) randomized clinical trial to help optimize therapy of unfavorable-risk patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, brachy boost, dose, extent, external beam, radiation, therapy, timing | Leave a comment »
The initial data from the ARCHES study of standard ADT + enzalutamide versus standard ADT + a placebo in men with metastatic, hormone-sensitive prostate cancer were reported earlier this year at the Genitourinary Cancers Symposium in San Francisco. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, apalutamide, darolutamide, deprivation, enzalutamide | 7 Comments »
According to the newest and largest known analysis of data currently available, there is a small but statistically significant association between treatment with androgen deprivation therapy (ADT) and increase in risk for Alzheimer’s disease and/or dementia over time. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, Alzheimer, androgen, association, dementia, deprivation | 10 Comments »
Depression is relatively common among men with prostate cancer. Indeed, it may be a lot more common than we can currently document. … READ MORE …
Filed under: Uncategorized | Tagged: ADT, androgen, cancer, depression, deprivation, prostae, risk | 3 Comments »
A newly published article in this month’s Journal of Urology has suggested that being exposed to Agent Orange and getting prostate cancer comes with better overall survival data than if one gets prostate cancer some other way. … READ MORE …
Filed under: Uncategorized | Tagged: ADT, agent, androgen, cancer-specific, deprivation, exposure, Orange, prostate, survival | 2 Comments »
Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, ARCHES, deprivation, enzalutamide, hormone, outcome, sensitive, standard, trial | 2 Comments »
We have long been bedeviled by questions about some of the short- and the long-term side effects and complications of androgen deprivation therapy (ADT) in the treatment of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, Alzheimer's, androgen, dementia, deprivation, failure, heart, side effect | 2 Comments »
